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ABSTRACT
Objectives: Coupled plasma filtration adsorption
(CPFA, Bellco, Italy), to remove inflammatory mediators
from blood, has been proposed as a novel treatment for
septic shock. This multicenter, randomised, non-
blinded trial compared CPFA with standard care in the
treatment of critically ill patients with septic shock.
Design: Prospective, multicenter, randomised, open-
label, two parallel group and superiority clinical trial.
Setting: 18 Italian adult, general, intensive care units
(ICUs).
Participants: Of the planned 330 adult patients with
septic shock, 192 were randomised to either have CPFA
added to the standard care, or not. The external
monitoring committee excluded eight ineligible patients
who were erroneously included.
Interventions: CPFA was to be performed daily for
5 days, lasting at least 10 h/day.
Primary and secondary outcome measures: The
primary endpoint was mortality at discharge from the
hospital at which the patient last stayed. Secondary
endpoints were: 90-day mortality, new organ
failures and ICU-free days within 30 days.
Results: There was no statistical difference in hospital
mortality (47.3% controls, 45.1% CPFA; p=0.76), nor in
secondary endpoints, namely the occurrence of new
organ failures (55.9% vs 56.0%; p=0.99) or free-ICU
days during the first 30 days (6.8 vs 7.5; p=0.35). The
study was terminated on the grounds of futility. Several
patients randomised to CPFA were subsequently found
to be undertreated. An a priori planned subgroup
analysis showed those receiving a CPFA dose
>0.18 L/kg/day had a lower mortality compared with
controls (OR 0.36, 95% CI 0.13 to 0.99).
Conclusions: CPFA did not reduce mortality in patients
with septic shock, nor did it positively affect other
important clinical outcomes. A subgroup analysis
suggested that CPFA could reduce mortality, when a
high volume of plasma is treated. Owing to the inherent
potential biases of such a subgroup analysis, this result
can only be viewed as a hypothesis generator and
should be confirmed in future studies.
ClinicalTrials.gov: NCT00332371;
ISRCTN24534559.
INTRODUCTION
The host response against pathogens is a
complex one. It is modulated through the
production of numerous mediators that,
among other mechanisms, promote proinﬂam-
matory and anti-inﬂammatory responses.1–4
The balance between these two pathways
heavily inﬂuences the outcome.4–9 The amount
and timing of release of different mediators,
their relatively short half-lives, their limited
range of action, their considerable redundancy
and pleiomorphisms and the underexpression
or overexpression of their receptors1 10–12 have
negatively affected the numerous therapeutic
attempts to neutralise speciﬁc molecules.12
The repeated failure of this strategy suggested
a potentially greater utility may be achieved
through simultaneous removal of several
mediators to rebalance the immune response.
This can be accomplished by various blood
puriﬁcation techniques, of which coupled
plasma ﬁltration adsorption (CPFA) can non-
selectively remove the majority of soluble
inﬂammatory mediators.13
Early experience with CPFA showed an
increased survival in a rabbit model of
endotoxin-induced septic shock.14 The ﬁrst
clinical study showed that a single treatment
lasting 10 h signiﬁcantly improved the haemo-
dynamic status.15 These preliminary observa-
tions were conﬁrmed in a study of 10 septic
shock patients in whom norepinephrine
requirements were progressively reduced and
eventually discontinued after an average of
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ﬁve daily CPFA sessions,16 without adverse events.
Subsequently, several Italian ICUs adopted CPFA in
septic shock patients with promising results, and were
willing to formally evaluate its efﬁcacy. GiViTI, the Italian
ICU network, thus launched a randomised multicentre
clinical trial to assess the efﬁcacy of CPFA in reducing
mortality of critically ill patients with septic shock.
METHODS
Written consent was obtained from the patient when
possible; otherwise physicians enroled patients according
to the article 4.8.15 of the Guidelines for Good Clinical
Practice.17.
Setting and participants
The study was performed in 18 adult ICUs who regularly
used CPFA in the treatment of septic shock. Patients
>18 years of age with septic shock either at or during
their admission to the ICU were eligible for study entry,
provided that CPFA could be started within 6 h from the
occurrence of hypotension refractory to ﬂuid resuscita-
tion. This was made by the attending physician (present
24/7) using explicit criteria.18 Reasons for exclusion
prior to randomisation were: pregnancy, cardiopulmon-
ary resuscitation, coma (GCS≤8) due to an organic cere-
bral disease, metastatic cancer, contraindication to a
haemopuriﬁcation technique, an estimated life expect-
ancy less than 2 weeks, prior inclusion in the study, admis-
sion from another ICU where the patient remained for
>24 h and lack of informed consent.
The Project Margherita electronic case report form
(eCRF) was used for this study.19 20 The core data
included demographics, admission diagnoses, severity of
infection on admission, comorbidities, location of the
patient prior to ICU admission, surgical status, reasons
for ICU admission, Simpliﬁed Acute Physiology Score II
(SAPS II) variables21 on admission, organ failures and
diseases occurring during their ICU stay, the severity of
infection reached, major procedures and interventions
and ICU and hospital outcomes. For enroled patients,
their clinical conditions, including the sequential organ
failure assessment (SOFA) score,22 the Risk of renal dys-
function, Injury to the kidney, Failure of kidney func-
tion, Loss of kidney function and End-stage kidney
disease (RIFLE) criteria22a for acute renal dysfunction
and CPFA parameters were collected at the time of ran-
domisation and then daily until ICU discharge or for a
maximum of 21 days. Interventions to assure study
homogeneity and quality are described in the online
supplementary material.
Randomisation and interventions
Eligibility criteria were ﬂagged up in real time by the
eCRF, which prompted the clinician to enrol the patient
or to register reasons for not doing so. Once enroled,
the patients were randomly allocated by the eCRF on a
1 : 1 basis to either have CPFA added to the standard
care, or not. A blocked randomisation schedule (ran-
domly permuting blocks of four and six)23 was imple-
mented in the eCRF, with stratiﬁcation according to the
centre and the presence of septic shock on admission.
The allocation was securely saved in the database and
revealed only once baseline additional data collection
were completed. All these procedures were implemen-
ted to guarantee allocation concealment.24
Coupled plasma filtration adsorption
CPFA was developed to non-speciﬁcally remove larger
mediators during systemic inﬂammation with an extra-
corporeal circuit consisting of a plasma ﬁlter, a resin
cartridge and a high-ﬂux dialyser.25
CPFA was performed with the use of a four-pump
modular treatment (Lynda, Bellco, Mirandola, Italy)
consisting of a plasma ﬁlter (0.45 m2 polyethersulfone)
and a following absorption on an unselective hydropho-
bic resin cartridge (140 mL for 70 g, with a surface of
about 700 m2/g) and a ﬁnal passage of the reconstituted
blood through a high-permeability 1.4 m2 polyethersul-
fone haemoﬁlter, in which convective exchanges may be
applied in a postdilution mode (ﬁgure 1).26
The postdilution reinfusion rate could be set up to
4 L/h. The blood ﬂow was maintained between 150 and
200 mL min, while the plasma ﬂow was controlled by a
ﬁltration fraction ranging from 10% to 18% of blood
ﬂow.27 More speciﬁcally, the ﬁltration fraction should be
set to 10% in the ﬁrst hour and then it should be grad-
ually increased to the target value of 18%. The
minimum volume of plasma treated per day should be
10 L, corresponding to a blood ﬂow of 150 mL min and
a ﬁltration fraction of 12%.
The reinfusion solution, sterile and pyrogen-free, with
bicarbonate buffer, contained the following composition
(mmol L): Na 140, K 1.5, Ca 2, Mg 0.75, Cl 108, bicar-
bonate 35, acetate 4 and glucose 5.55.
All ﬂuids were administered at room temperature.
During treatment, the patient’s temperature was to be
maintained possibly within physiological limits, and
anyway higher than 35°C. The anticoagulation protocol
is described in the online supplementary material.
According to the available clinical evidence, CPFA was
to be repeated daily for the ﬁrst 5 days, lasting at least
10 h each time, so that an average of 0.15 L/kg/day of
plasma should have been treated per day.
Outcomes, follow-up and plan of analysis
The primary endpoint was mortality at discharge from
the hospital in which the patients were last treated.
Thus, for patients transferred to another hospital, mor-
tality was assessed at the discharge from the hospital in
which the patients last stayed. To minimise the bias due
to the decision to have the relative dying at home,
patients discharged in a terminal condition (life expect-
ancy <2 weeks as estimated by the attending physician)
were considered to have died at the time of hospital dis-
charge. The primary analysis was by intention-to-treat;
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however, a per-protocol analysis was also planned to
assess the impact of protocol violations, if any, on the
primary endpoint. Secondary endpoints were: mortality
within 90 days of randomisation; the proportion of
patients who developed ≥1 new organ failures during
their ICU stay (deﬁned by an organ SOFA score of 3
or 422) and ICU-free days during the ﬁrst 30 days from
randomisation.
Timing of intervention is considered extremely
important in septic shock. Thus, two subgroup analyses
of the primary endpoint were pre-planned, namely the
assessment of outcomes in patients with septic shock on
ICU admission or who developed it during their ICU
stay and patients starting CPFA within or later than 4 h
of randomisation.
The study was sized to have 80% power to detect an
improvement in hospital mortality from an expected
63% in the controls to 47% with CPFA (25% relative
improvement), with a two-tailed 5% type I error. A total
of 330 patients were required. A Bayesian approach (see
online supplementary material) was adopted for interim
analyses.23
Premature termination of the trial
In November 2010, the External Data and Safety
Monitoring Committee (EDSMC) prompted an early
termination of the study on the grounds of futility. To
reach the a priori determined goal of a 25% reduction
in mortality, in the second part of the study, a 23%
hospital mortality in the CPFA group would have been
required, which was considered implausible. Further
concerns were the low recruitment rate and the high
number of protocol violations in the CPFA arm in terms
of low volume of plasma treated per day.
Statistical analyses
Hospital mortality was analysed using the χ2 test. The
effect size was expressed in terms of absolute risk differ-
ence with its 95% CI.28 With regard to secondary end-
points and subgroup analyses, categorical variables were
compared with χ2 or Fisher’s exact tests, while a Student
t test was used for continuous variables, after having
assessed normality through the Kolmogorov-Smirnov,
the Shapiro-Wilks tests and the normal probability plot,
and homoscedasticity through the Levene’s test.
Mortality within 90 days of randomisation was assessed
using Kaplan-Meier curves with any differences investi-
gated through logrank testing.
As a number of protocol violations in the CPFA arm
were registered due to a lower than planned volume of
plasma treated, we also performed a per-protocol ana-
lysis of the primary endpoint, as determined a priori.
The analysis by the ‘adhesion to the protocol’ was
indeed planned to involve patients who did not have
relevant protocol violations, to assess the possible inﬂu-
ence of such violations on the outcome.
Hospital mortality was evaluated according to tertiles
of the mean volume of plasma treated per kg per day.
Figure 1 Coupled plasma filtration adsorption schema.
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Any association between tertiles and hospital mortality
was tested with the χ2 test and the Cochran-Armitage
test for trend. As any beneﬁt of randomisation was
lost, comparison with the control group was per-
formed through a logistic regression model that
allowed to adjust for possible confounders (see online
supplementary material).
RESULTS
Between January 2007 and November 2010, a total of
192 patients had been randomised. Recruitment in each
ICU lasted a median of 22 months (IQR 13–26). During
this period, 386 patients with septic shock were excluded
as being non-eligible (see online supplementary mater-
ial). Central monitoring subsequently identiﬁed 14
enroled patients whose eligibility criteria were doubtful.
Further clinical information was retrieved and provided
to the EDSMC who determined that eight of these
patients (5 CPFA, 3 control) were erroneously enroled
(see online supplementary material). Analysis was per-
formed by intention-to-treat on the 184 remaining
patients.29 Figure 2 denotes the ﬂow of participants.
Table 1 shows the patients’ characteristics; further
details are provided in the online supplementary mater-
ial. One episode of surgical wound bleeding was regis-
tered as possibly related to CPFA in a patient receiving
drotrecogin alfa (activated).
Overall, 44 patients (48.4%) had less than the minimum
amount, as recommended by the protocol, of plasma
treated over the ﬁrst 5 days. They were evenly distributed
across centres. To better express and investigate the phe-
nomenon of undertreatment, and following the emerging
concept of dose of renal replacement therapy,30 we com-
puted the volume of plasma treated in L/kg/day. In the
91 patients randomised in the CPFA arm, a mean of
0.15 L/kg/day were treated for the ﬁrst 5 days (tertiles
0.12–0.18), and 0.18 for the ﬁrst 3 days. Table 2 lists the
reasons for undertreatment. Four patients died during
CPFA, one before initiating the treatment, two at the very
ﬁrst moment and one after the ﬁrst 0.09 L kg of plasma
treated. The mean time to start CPFA after septic shock
identiﬁcation was 5.7 h (SD 3.8); 38 patients started within
4 h. In the control group, in violation of the protocol, two
patients were treated with CPFA; one died at 7 days post-
randomisation, the other was discharged alive from the
hospital 37 days after randomisation.
Figure 2 Flow chart of participants.
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Table 1 Characteristics of the patients before randomisation
Controls (n=93) CPFA (n=91)
Sex (male), n (%) 65 (69.9) 56 (61.5)
Age (years), n (%)
Overall, mean [SD] 64.9 [13.3] 63.6 [14.4]
17–45 10 (10.8) 9 (9.9)
46–65 34 (36.6) 35 (38.5)
66–75 23 (24.7) 27 (29.7)
>75 26 (28.0) 20 (22.0)
BMI (%)
Underweight 5 (5.4) 2 (2.2)
Normal weight 34 (36.6) 27 (29.7)
Overweight 24 (25.8) 31 (34.1)
Obese 30 (32.3) 31 (34.1)
Length of stay before ICU admission (days), mean [SD] 6.5 [13.8] 6.2 [11.8]
Source of admission, n (%)
Emergency room 16 (17.2) 31 (34.1)
Surgical ward 43 (46.2) 31 (34.1)
Medical ward 29 (31.2) 27 (29.7)
Other ICU 5 (5.4) 2 (2.2)
Surgical status, n (%)
Not surgical 43 (46.2) 54 (59.3)
Elective surgical 8 (8.6) 6 (6.6)
Emergency surgical 42 (45.2) 31 (34.1)
Trauma, n (%) 6 (6.5) 5 (5.5)
Comorbidities, n (%)
None 12 (12.9) 18 (19.8)
Mary Charlson Index, median [Q1–Q3] 2 [0–3] 1 [0–2]
Reason for admission, n (%)
Monitoring/weaning 7 (7.5) 7 (7.7)
Respiratory failures 80 (86.0) 69 (75.8)
Cardiovascular failures 50 (53.8) 58 (63.7)
Neurological failures 12 (12.9) 9 (9.9)
Renal failure 24 (25.8) 33 (36.3)
Multiple organ failures 59 (63.4) 65 (71.4)
Top 3 non-infectious diseases on admission, n (%)
Metabolic disorder 23 (24.7) 25 (27.5)
Gastrointestinal perforation 16 (17.2) 15 (16.5)
ALI 16 (17.2) 14 (15.4)
SAPS II on admission, median [Q1–Q3] 53 [43–67] 51 [42–65]
SOFA at randomisation, median [Q1–Q3] 9 [8–11] 9 [8–11]
RIFLE at randomisation, n (%)
No risk 51 (54.8) 29 (31.9)
Risk 16 (17.2) 22 (24.2)
Injury 10 (10.8) 21 (23.1)
Failure 16 (17.2) 19 (20.9)
Septic shock on admission, n (%)
Missing 39 (42.4) 43 (47.8)
1 1
Site of infection, n (%)
Pneumonia 25 (26.9) 30 (33.0)
Peritonitis 28 (30.1) 25 (27.5)
Primary bacteraemia 1 (1.1) 8 (8.8)
Colecistitis/colangitis 5 (4.3) 3 (3.3)
Urinary tract infection 1 (1.1) 2 (2.2)
Other 23 (24.7) 19 (20.9)
Multisite 10 (10.8) 4 (4.4)
Top five microorganisms isolated, n (%)
Non-ESBL producing Escherichia coli 13 (13.7) 14 (15.9)
Candida albicans 4 (4.2) 6 (6.8)
Continued
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No statistical difference was found in hospital mortality
with 47.3% dying in the control group (44/93) versus
45.1% dying in the CPFA group (41/91, p=0.76), with
an absolute risk difference of 2.2% (95% CI −12.2% to
16.6%). The 90-day survival curves of the two groups
substantially overlapped (logrank test, p=0.48; ﬁgure 3).
Secondary endpoints did not statistically differ: the
occurrence of new organ failure was 55.9% in the
control versus 56% for CPFA patients (p=0.99); the free
ICU days during the ﬁrst 30 days postrandomisation
were 6.8 in the control group versus 7.5 in the CPFA
group (p=0.35). There were also no statistical differ-
ences in the a priori determined subgroups. Hospital
mortality in patients with septic shock on ICU admission
was comparable (16/39 (41%) for control vs 19/43
(44.2%) for CPFA; p=0.77). The same was observed for
the subgroup of patients who developed septic shock
during their ICU stay (27/53 (50.9%) control vs 21/47
(44.7%) CPFA; p=0.53). Likewise, no statistical differ-
ence in mortality was observed between controls 44/93
(47.3%), and patients starting CPFA within 4 h from ran-
domisation (17/38 (44.7%); p=0.88), nor in those who
started CPFA after 4 h (20/46 (43.5%); p=0.76). In
seven patients, the timing of CPFA initiation was
missing. Eventually, no effect on the number of patients
per ICU was observed.
The per-protocol analysis revealed a non-signiﬁcant
trend in hospital mortality according to the tertiles of
volume of plasma treated per kg per day over the ﬁrst
5 days (ﬁgure 4). The characteristics of the groups
deﬁned by the tertiles are shown in the online supple-
mentary material. The logistic regression model, aimed
at adjusting for possible confounders, veriﬁed that hos-
pital mortality in patients falling within the third tertile
(≥0.18 L/kg/day of plasma treated over the ﬁrst 5 days)
was statistically lower than in the control group (OR 0.36,
95% CI 0.13 to 0.99; see table 3). We then performed two
sensitivity analyses, namely limiting the evaluation of the
volume of plasma treated to the ﬁrst 3 days and excluding
from the control and treated groups patients who died in
the ﬁrst 24 h postrandomisation. The ﬁrst analysis was
aimed at assessing whether any possible beneﬁt of CPFA
was obtained before 5 days; the second was intended to
minimise any possible selection bias as patients who died
early could not have entered the highest tertile of treated
plasma due to insufﬁcient time. Both sensitivity analyses
(presented in the online supplementary material) con-
ﬁrmed the same estimates, even though statistical signiﬁ-
cance was lost for lack of power.
DISCUSSION
The prognosis of critically ill patients with septic shock
remains poor, with mortality rates still around 50–
60%.20 31 All attempts to ﬁnd a ‘magic bullet’ to restore
immune derangements during sepsis and improve the
outcomes have failed, highlighting the complexity of the
immune response, including a marked intrapatient vari-
ability in terms of magnitude of response, timing and
trajectory and our continued lack of full understanding.
Rather than targeting a speciﬁc molecule, CPFA
offered a more general means of reducing the circulat-
ing inﬂammatory mediator load. Following promising
results in early phase studies,15 16 25 GiViTI performed
this randomised clinical trial to assess the efﬁcacy of
CPFA in reducing hospital mortality of patients affected
by septic shock.
The main findings
After randomising more than half the planned number
of patients, we found no statistical difference with the
use of CPFA in hospital mortality, the occurrence of new
organ failures or the overall clinical evolution. To
Table 1 Continued
Controls (n=93) CPFA (n=91)
Methicillin-resistant Staphylococcus aureus 10 (10.5) 4 (4.5)
Penicillin sensitive Pneumococcus 2 (2.1) 4 (4.5)
Ampicillin-resistant vancomycin-sensitive Enterococcus faecalis 3 (3.2) 3 (3.4)
Gram-positive bacteria 25 (26.3) 27 (30.7)
Gram-negative bacteria 29 (30.5) 27 (30.7)
Q1–Q3=first and third quartiles; underweight=for male, BMI<20, for woman, BMI<19; normal weight=for man, BMI 20–25, for woman, BMI
19–24; overweight=for male, BMI 25–30, for female, BMI 24–29; obese=for male, BMI>30, for female, BMI>29; respiratory failure=need of
ventilatory support to maintain gas exchange; cardiovascular failure=need of vasoactive drugs to provide sufficient pump action; neurological
failures (GCS≤8); Renal failure=RIFLE score: injury or higher.
ALI, acute lung injury; BMI, body mass index; CPFA, coupled plasma filtration adsorption; ESBL, extended-spectrum β-lactamase; GCS,
Glasgow Coma Scale; ICU, intensive care unit; RIFLE, Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of
kidney function and End-stage kidney disease; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment.
Table 2 Reasons for undertreatment in the coupled
plasma filtration adsorption arm (n=44)
n Per cent
Clotting of the circuit 21 47.7
Technical problems 5 11.4
Organisational problems 4 9.1
Patient’s death 4 9.1
Lack of specialised personnel 3 6.8
Family request to stop CPFA 1 2.3
Other 6 13.6
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reverse these results, with the sample still to be rando-
mised, implausible data should have been observed
from then on. Furthermore, this study was powered
from an anticipated 63% hospital mortality in the
control group. Although such an estimation, coming
from previous GiViTI data, was conﬁrmed in the whole
sample (ﬁgure 2), the eligibility criteria selected a sub-
group where mortality was sensibly lower (47.3%),
thereby reducing the power of the study. Thus, the
EDSMC considered that continuing to spend money in
a clinical trial that had a little chance of demonstrating
efﬁcacy was undesirable and asked for a premature ter-
mination on the grounds of futility, although the antici-
pated, non-binding Bayesian futility criteria for stopping
the trial were not fulﬁlled.
The dilemma of primary endpoint
The correct primary endpoint of clinical trials in septic
shock is still debated.32 Most of the studies have adopted
28-day mortality due to Food and Drug Administration
stipulations. However, the mortality rate attributable to
sepsis continues long after the initiation of the acute
event33; indeed, 16.8% of our study patients were still in
the ICU beyond 28 days after randomisation. On the
other hand, overextending the follow-up period has
the disadvantage of diluting the phenomenon, with the
inclusion of competing causes of death. We thus consid-
ered mortality at the time of discharge from the hospital
into which they were last admitted following their septic
shock episode. At that point, the patient no longer
requires aggressive, specialised, interdisciplinary care,
which means he or she had survived the septic shock
episode. A 90-day mortality was anyway recorded and
considered as secondary endpoint.
The problem of undertreatment
Nearly half of the patients randomised to CPFA were
undertreated as per protocol stipulation. This poses two
Figure 3 Survival curves.
Figure 4 Hospital mortality
according to the quantity of
volume of plasma treated
(whiskers represent 95% CI).
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crucial questions: the true feasibility of the technique in
the ICU and the possible relationship between the
overall negative result and such undertreatment. The
main reason for not reaching the prescribed volume of
plasma treated was clotting of the circuit (48%). This
problem was encountered by all centres.
Why did the training of the centres not have an
effect? Many factors could have contributed. First, CPFA
involves a complex circuit that includes a haemoﬁlter, a
plasma ﬁlter and an adsorbing cartridge, and requires
an adequate balance of ﬂows, dilutions and anticoagula-
tion. We used heparin for anticoagulation (see online
supplementary material), the most frequently used drug
in this regard, because the machine used in the study
did not support regional anticoagulation with citrate.
Nevertheless, heparin is difﬁcult to manage, particularly
in the critically ill. Many centres may have been too con-
servative either with the heparin dosage and/or the
blood ﬂow rate through the circuit, or there may be an
insufﬁcient antithrombin substrate for the heparin to be
effective.34 Second, because of the high cost of the pro-
cedure (about €1.200 per treatment), in most of the
cases, the physicians did not start a new course of CPFA
on the same day, in case of clotting of the circuit. Third,
the training may have been (partly) ineffective. On the
one hand, it only reached a few people per ICU. It was
often difﬁcult to involve the nephrologists, who, in many
centres, are in charge of the procedure. On the other
hand, despite excellent feedbacks from the participants,
we cannot a posteriori exclude it was qualitatively
suboptimal.
At any rate, the feasibility problems we have encoun-
tered in the present clinical trial suggest that the proced-
ure, as implemented in this study, is not practicable in
everyday clinical practice. Interestingly, regional anticoa-
gulation with citrate represents a valid alternative to
heparin as its anticoagulatory effect is limited to the
extracorporeal circuit, without any systemic effect, and
can be safely applied in the ICU.35 36 In a feasibility
study carried out in 13 patients at high risk of bleeding,
citrate regional anticoagulation was associated with a
signiﬁcantly lower number of clotted CPFA cartridges
than with the heparin.37 The newer generation CPFA
machine is able to apply citrate regional anticoagulation,
and initial experiences in patients with septic shock
demonstrate that a much higher volume of plasma can
be safely treated.38 Should these preliminary results be
conﬁrmed, the question whether the reason of our
negative result was a problem of feasibility or efﬁcacy
would become essential, to avoid the risk of dismissing a
potentially effective treatment for such a high mortality
condition as septic shock.
The per-protocol analysis and its limits
Of note, patients who had a larger volume of plasma
treated seemed to have reduced hospital mortality. This
cannot be taken as conclusive evidence of the efﬁcacy of
CPFA. Even though the per-protocol analysis was
planned a priori with the expected direction of the
effect being stated in advance, and a dose–response rela-
tionship was found, a number of potential problems
threaten the validity of this result. First, a subgroup def-
inition for the per-protocol analysis (ie, tertiles of
plasma treated) was based on characteristics measured
after randomisation. Under such circumstances, the allo-
cation to a subgroup may have been inﬂuenced by the
intervention in relation to the severity of the patient,
causing an important bias. This would be the case, for
example, if the probability of circuit clotting was higher
in the more severely ill patients. Actually, the character-
istics of the three subgroups were somewhat unbalanced
(see online supplementary material). We adjusted for
possible confounders in the multivariate model to min-
imise this risk, but we were limited to prognostic factors
collected in the database. Particularly, we have no data
on the immunoinﬂammatory status of the patients to
account for. Second, the subgroup allocation may have
been inﬂuenced by the outcome. For example, early
deaths could have prevented the treatment of high
volume of plasma. Even if we standardised the treated
volume to the duration in hours of CPFA, since the treat-
ment started with a low ﬁltration fraction to be gradually
Table 3 Results of the logistic regression model on hospital mortality
Variable OR 95% CI p Value
Volume of plasma treated (L/kg/day)
CPFA, ≤0.18 (1° and 2° tertiles) vs controls 1.52 0.73 to 3.17 0.033
CPFA, >0.18 (3° tertile) vs controls 0.36 0.13 to 0.99
Age (decades) 1.57 1.19 to 2.07 0.001
Source of admission
Other ICU vs medical ward 0.28 0.04 to 1.89
Emergency room vs medical ward 0.27 0.11 to 0.67 0.021
Surgical ward vs medical ward 0.34 0.15 to 0.77
Renal failure at admission 4.08 1.47 to 11.32 0.007
Cholecystitis or cholangitis on admission 0.18 0.04 to 0.75 0.018
Dependent variable: hospital mortality. Number of patients = 184. Prediction: likelihood ratio test: 39.93, degrees of freedom: 8, p<0.0001;
% pairs: concordant 77.4%; discordant 22.2%; Somers’ D: 0.55; receiver operating characteristic (ROC) curve area: 0.78. Goodness of fit
Hosmer-Lemeshow goodness-of-fit C test: 8.22; eight degrees of freedom; p value = 0.41.
ICU, intensive care unit.
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increased to the target value (see online supplementary
material), the ﬁrst hours were characterised by a certain
degree of undertreatment by design. In this case, an
early death could have prevented the patient from being
included in the third tertile, but not in the others, nor
in the controls, spuriously inﬂuencing the result. We
performed a sensitivity analysis by excluding early deaths
from all groups, knowing that such an analysis could
have greatly disadvantaged CPFA, if the lower number of
early deaths were due to the efﬁcacy of the technique.
Interestingly, we veriﬁed that the strength of association
was unchanged, albeit losing statistical signiﬁcance for
a lack of power, thereby excluding the presence of a
differential outcome-related selection bias. Finally, the
statistical signiﬁcance of our results is quite thin; indeed,
just one more death in the highest tertile subgroup
would have rendered the difference in hospital mortality
non-signiﬁcant.
Study limitations
Almost 60% of patients with septic shock did not meet
the inclusion criteria. The main reason was life expect-
ancy less than 2 weeks. The mortality of these patients
was in fact 98%. Nonetheless, we cannot exclude that
the higher severity could have brought about a poten-
tially greater possibility of response to intervention, at
least for some patients. Future studies should consider
this aspect.
One-third of the eligible patients were not randomised
due to the very narrow window (6 h) for the patient’s
recruitment and initiation of the treatment. This would
have particularly hampered the generalisability of results
had the ﬁndings been positive.
Finally, the study was terminated early for reasons of
futility, after almost 60% of the originally planned
patients had been recruited. This reduced the possibility
of studying phenomena emerging from the analyses
with a signiﬁcant power, as in the case of the volume of
plasma treated. In any event, any subgroup analysis,
regardless of the involved sample size, could only have
generated hypotheses. Our interpretation of the ﬁndings
is in itself a hypothesis, which would have been only
more robust with a larger sample.
CONCLUSION
CPFA was not able to reduce mortality in patients with
septic shock. This result strongly discourages the use of
CPFA in the everyday clinical practice, as it was imple-
mented in this study. Unfortunately, we were not able to
discern whether the culprit of such a negative result was
the lack of effectiveness (mainly due to widespread feasi-
bility problems) rather than the lack of true efﬁcacy.
The subgroup analysis was suggestive of efﬁcacy, if a
high volume of plasma was treated. Although we have
taken counter measures to minimise potential biases,
these cannot be completely excluded. Hence, this result
can only be viewed as hypothesis generating. Given the
new availability of citrate regional anticoagulation, we
have designed a conﬁrmatory, adaptive trial whose ﬁrst
step will be to prove this new technique easily allows
high volume of plasma treated with CPFA.
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